Report Date: Tuesday, August 4, 2026 (before market open) | Current Price: ~$374.78 (Aug 3 close)
Waters is heading into this print roughly six months after closing its transformative combination with Becton, Dickinson's Biosciences and Diagnostic Solutions (BDS) business on February 9, 2026 — a Reverse Morris Trust deal that roughly doubled the company's revenue base and reorganized Waters into four segments: Analytical Sciences, Biosciences, Advanced Diagnostics, and Materials Sciences. This is only the second quarterly report reflecting the combined entity, so investors will be scrutinizing both the legacy instrument business's organic momentum and early proof points on integration/synergy execution.
Q1 was a blowout print that reset expectations higher: - total company as reported revenue was $1.267 billion, comprising of $747 million of organic revenue and $520 million of Biosciences and Diagnostic Solutions following the February 9 acquisition closing date. Organic revenue grew 13% as reported and 11% in constant currency, exceeding the high end of our constant currency guidance range by approximately 200 basis points. - Biosciences and Diagnostic Solutions revenue exceeded guidance by $40 million and grew an estimated 7% on a reported basis versus the prior year equivalent period. - Adjusted EPS grew 20% year-over-year to $2.70 per share, exceeding the high end of our guidance range by $0.35.
Management used the beat to raise full-year guidance: the Company is raising its full-year 2026 organic, constant currency revenue growth guidance to the range of 6.5% to 8.0%... The Company now expects full-year 2026 acquired business reported revenue of approximately $3.035 billion on an owned-period basis... Total Company reported revenue for full-year 2026 is expected to be in the range of $6.405 billion to $6.455 billion... The Company is raising its full-year 2026 adjusted EPS guidance to $14.40 to $14.60.
The stock reacted sharply positively, jumping from ~$302 to ~$343 the day of the Q1 report and grinding higher through the summer to the high-$370s/low-$380s range currently.
Management's own Q2 guidance, issued alongside Q1 results, is the key benchmark for tomorrow: - The Company expects second quarter 2026 organic constant currency revenue growth to be in the range of 6.0% to 8.0%... second quarter 2026 organic reported revenue is expected to be in the range of $814 million to $829 million. The Company expects acquired business reported revenue for the second quarter 2026 to be approximately $802 million. Total Company reported revenue for the second quarter of 2026 is expected to be in the range of $1.616 billion to $1.631 billion. - The Company expects second quarter 2026 adjusted EPS to be in the range of $2.95 to $3.05, which represents flat to 3.4% year-over-year adjusted EPS growth.
Notably, management explicitly flagged that Q2 EPS growth would look muted versus other quarters because it falls ahead of cost synergies and business-level cost actions, which only start hitting the P&L in Q3: Second quarter adjusted earnings per fully diluted share is expected to be in the range of $2.95 to $3.05, which is flat to 3.4% growth given the full burden of higher interest costs and newly issued shares and ahead of cost synergies and business level cost action benefits that begin to flow through the P&L starting in the third quarter.
Consensus is sitting essentially in line with, or slightly above, the top end of guidance: analysts expect Waters to post earnings of $3.01 per share and revenue of $1.6223 billion for the quarter, against management's guided range of $2.95–$3.05 EPS and $1.616–$1.631B revenue. One preview noted this sets up a modest "beat-the-whisper" dynamic since the Q2 adjusted EPS guidance midpoint of ~$3.00 is a touch below the ~$3.03 street consensus, a dynamic some see as conservative given Waters' recent beat-and-raise pattern — the company has topped EPS estimates in each of its last four quarters. Sell-side sentiment remains constructive: Waters carries a consensus "Buy" rating from roughly 15–22 analysts, with average price targets in the ~$400–$413 range, implying high-single to low-double-digit upside from current levels.
1. Is the BDS "180-day plan" still outperforming? Management's early narrative centered on rapid operational fixes at the newly acquired Biosciences and Diagnostic Solutions units — tighter funnel/forecast discipline, new pricing "deal desks," and reagent-rental-contract compliance reviews. On the Q1 call, CFO Amol Chaubal noted on the legacy Waters business, we did roughly a little over 200 basis points of price... On the BD business, we did just about 0.5 percentage of price, which is in line with how BD has been doing historically... We do see a very meaningful opportunity to bring the BD business where our legacy Waters business is. Investors should watch whether Biosciences and Diagnostic Solutions pro forma growth continued to inflect from the -1% (Biosciences) and +1% (Diagnostic Solutions) full-quarter pro forma rates seen in Q1, and whether pricing/reagent-rental actions are showing up in the numbers yet.
2. China localization progress for flow cytometry. A major swing factor: management committed to localizing flow cytometry manufacturing in China (Suzhou site) to combat export-control and DRG headwinds, with the benefit expected to start in Q3: We intend to begin manufacturing key products in China for China starting in the third quarter, which is already providing our team a strong impetus to begin competing for tenders that require local manufacturing. Any commentary on order flow ahead of that Q3 ramp will be closely watched, especially since China flow clinical revenue declined 25% in Q1 due to DRG headwinds while ex-China grew double digits.
3. Cost synergies beginning to hit the P&L. The $55 million 2026 cost-synergy target and broader restructuring were described as "on track," with savings expected to start flowing through starting in Q3 — meaning Q2 margins should still look similar to Q1's pre-synergy run-rate, but guidance/commentary on Q3 ramp will matter for the stock. On cost synergies, we remain firmly on track to deliver our $55 million target for 2026... The associated savings will hit the P&L beginning in the third quarter of this year.
4. Legacy Analytical Sciences momentum — durable or pulled-forward? The legacy business (still ~55% of organic revenue) grew a stunning 12% constant currency in Q1, led by mid-teens chemistry growth and high-single-digit instrument growth, driven by the LC-MS replacement cycle, GLP-1/PFAS/biologics/India-generics tailwinds, and China pharma strength (>50% growth). Management flagged some Q1 strength was inflated by ~4 extra selling days and cautioned the back half is guided more conservatively (~6% constant-currency organic growth) versus a ~9% first-half run rate, partly to "derisk" the outlook. Watch whether Q2 organic growth confirms this deceleration is intentional prudence rather than a real slowdown.
5. New product launch cadence. Key products to track: the BACTEC FXI next-gen blood-culture system (CE-marked, launched in Europe/Japan, U.S./other approvals pending, timeline accelerated 3–5 months versus BD's original plan) and the BD Onclarity HPV self-collection kit (FDA-cleared, contract signings underway) — both potential above-plan revenue-synergy contributors via instrument replacement.
6. Leverage, cash flow, and macro cost pressures. The deal added ~$5.3 billion of debt, and Q1 free cash flow was a $42 million outflow (impacted by deal-related costs and TSA/net-cash-settlement timing with BD) versus $234 million of adjusted free cash flow a year ago. Management also flagged ongoing efforts to fully offset freight, raw material, and component cost pressure tied to the Middle East conflict for the balance of the year — a live macro risk given the broader tape's focus on rising oil-driven input costs this summer. Progress on working-capital normalization (DSO, BD-related receivables/payables under the TSA) and confirmation of the ~$186 million full-year net interest expense assumption are also worth tracking.
Going into this print, the setup is constructive but not undemanding: Waters beat and raised decisively in Q1, management has deliberately "derisked" second-half guidance (implying only ~6% organic constant-currency growth versus a >9% first-half pace) to create room for upside, and the stock has already re-rated meaningfully off its post-deal-close lows near $320 back toward its pre-deal highs above $380–400. With consensus estimates ($3.01 EPS, ~$1.62B revenue) sitting near the top of management's own guidance range, the bar for a "clean beat" is real, and the more important signals for the stock may be qualitative: evidence that BDS integration synergies and China flow-cytometry localization are tracking to start contributing in Q3, that cost-synergy realization is on schedule, and that legacy Analytical Sciences growth — while decelerating from an unusually strong Q1 — remains durable into the second half.